Home > Research > Publications & Outputs > Artesunate versus quinine for treating severe m...
View graph of relations

Artesunate versus quinine for treating severe malaria

Research output: Contribution to journalJournal article

Published

Standard

Artesunate versus quinine for treating severe malaria. / Sinclair, David; Donegan, Sarah; Isba, Rachel; Lalloo, David G.

In: Cochrane Database of Systematic Reviews, Vol. n/a, No. 6, CD005967, 2012.

Research output: Contribution to journalJournal article

Harvard

Sinclair, D, Donegan, S, Isba, R & Lalloo, DG 2012, 'Artesunate versus quinine for treating severe malaria', Cochrane Database of Systematic Reviews, vol. n/a, no. 6, CD005967. https://doi.org/10.1002/14651858.CD005967.pub4

APA

Sinclair, D., Donegan, S., Isba, R., & Lalloo, D. G. (2012). Artesunate versus quinine for treating severe malaria. Cochrane Database of Systematic Reviews, n/a(6), [CD005967]. https://doi.org/10.1002/14651858.CD005967.pub4

Vancouver

Sinclair D, Donegan S, Isba R, Lalloo DG. Artesunate versus quinine for treating severe malaria. Cochrane Database of Systematic Reviews. 2012;n/a(6). CD005967. https://doi.org/10.1002/14651858.CD005967.pub4

Author

Sinclair, David ; Donegan, Sarah ; Isba, Rachel ; Lalloo, David G. / Artesunate versus quinine for treating severe malaria. In: Cochrane Database of Systematic Reviews. 2012 ; Vol. n/a, No. 6.

Bibtex

@article{fe00a4ab869c445ababb139920b4d1c3,
title = "Artesunate versus quinine for treating severe malaria",
abstract = "BackgroundSevere malaria results in over a million deaths every year, most of them in children aged under five years and living in sub-Saharan Africa. This review examines whether treatment with artesunate, instead of the standard treatment quinine, would result in fewer deaths and better treatment outcomes.ObjectivesTo compare artesunate with quinine for treating severe malaria.Search methodsWe searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library), MEDLINE, EMBASE, LILACS, ISI Web of Science, the metaRegister of Controlled trials (mRCT), conference proceedings, and reference lists of articles to November 2010.Selection criteriaRandomized controlled trials comparing intravenous, intramuscular, or rectal artesunate with intravenous or intramuscular quinine for treating adults and children with severe malaria who are unable to take medication by mouth.Data collection and analysisTwo authors independently assessed the eligibility and risk of bias of trials, and extracted and analysed data. The primary outcome was all-cause death. Dichotomous outcomes were summarized using risk ratios (RR) and continuous outcomes by mean differences (MD). Where appropriate, we combined data in meta-analyses.Main resultsEight trials enrolling 1664 adults and 5765 children are included in this review.Treatment with artesunate significantly reduced the risk of death both in adults (RR 0.61, 95{\%} Confidence Interval (CI) 0.50 to 0.75; 1664 participants, five trials) and children (RR 0.76, 95{\%} CI 0.65 to 0.90; 5765 participants, four trials)In children, treatment with artesunate increased the incidence of neurological sequelae at the time of hospital discharge. The majority of these sequelae were transient and no significant difference between treatments was seen at later follow up.Authors' conclusionsThe evidence clearly supports the superiority of parenteral artesunate over quinine for the treatment of severe malaria in both adults and children and in different regions of the world.",
author = "David Sinclair and Sarah Donegan and Rachel Isba and Lalloo, {David G}",
year = "2012",
doi = "10.1002/14651858.CD005967.pub4",
language = "English",
volume = "n/a",
journal = "Cochrane Database of Systematic Reviews",
issn = "1469-493X",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

RIS

TY - JOUR

T1 - Artesunate versus quinine for treating severe malaria

AU - Sinclair, David

AU - Donegan, Sarah

AU - Isba, Rachel

AU - Lalloo, David G

PY - 2012

Y1 - 2012

N2 - BackgroundSevere malaria results in over a million deaths every year, most of them in children aged under five years and living in sub-Saharan Africa. This review examines whether treatment with artesunate, instead of the standard treatment quinine, would result in fewer deaths and better treatment outcomes.ObjectivesTo compare artesunate with quinine for treating severe malaria.Search methodsWe searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library), MEDLINE, EMBASE, LILACS, ISI Web of Science, the metaRegister of Controlled trials (mRCT), conference proceedings, and reference lists of articles to November 2010.Selection criteriaRandomized controlled trials comparing intravenous, intramuscular, or rectal artesunate with intravenous or intramuscular quinine for treating adults and children with severe malaria who are unable to take medication by mouth.Data collection and analysisTwo authors independently assessed the eligibility and risk of bias of trials, and extracted and analysed data. The primary outcome was all-cause death. Dichotomous outcomes were summarized using risk ratios (RR) and continuous outcomes by mean differences (MD). Where appropriate, we combined data in meta-analyses.Main resultsEight trials enrolling 1664 adults and 5765 children are included in this review.Treatment with artesunate significantly reduced the risk of death both in adults (RR 0.61, 95% Confidence Interval (CI) 0.50 to 0.75; 1664 participants, five trials) and children (RR 0.76, 95% CI 0.65 to 0.90; 5765 participants, four trials)In children, treatment with artesunate increased the incidence of neurological sequelae at the time of hospital discharge. The majority of these sequelae were transient and no significant difference between treatments was seen at later follow up.Authors' conclusionsThe evidence clearly supports the superiority of parenteral artesunate over quinine for the treatment of severe malaria in both adults and children and in different regions of the world.

AB - BackgroundSevere malaria results in over a million deaths every year, most of them in children aged under five years and living in sub-Saharan Africa. This review examines whether treatment with artesunate, instead of the standard treatment quinine, would result in fewer deaths and better treatment outcomes.ObjectivesTo compare artesunate with quinine for treating severe malaria.Search methodsWe searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library), MEDLINE, EMBASE, LILACS, ISI Web of Science, the metaRegister of Controlled trials (mRCT), conference proceedings, and reference lists of articles to November 2010.Selection criteriaRandomized controlled trials comparing intravenous, intramuscular, or rectal artesunate with intravenous or intramuscular quinine for treating adults and children with severe malaria who are unable to take medication by mouth.Data collection and analysisTwo authors independently assessed the eligibility and risk of bias of trials, and extracted and analysed data. The primary outcome was all-cause death. Dichotomous outcomes were summarized using risk ratios (RR) and continuous outcomes by mean differences (MD). Where appropriate, we combined data in meta-analyses.Main resultsEight trials enrolling 1664 adults and 5765 children are included in this review.Treatment with artesunate significantly reduced the risk of death both in adults (RR 0.61, 95% Confidence Interval (CI) 0.50 to 0.75; 1664 participants, five trials) and children (RR 0.76, 95% CI 0.65 to 0.90; 5765 participants, four trials)In children, treatment with artesunate increased the incidence of neurological sequelae at the time of hospital discharge. The majority of these sequelae were transient and no significant difference between treatments was seen at later follow up.Authors' conclusionsThe evidence clearly supports the superiority of parenteral artesunate over quinine for the treatment of severe malaria in both adults and children and in different regions of the world.

UR - http://www.scopus.com/inward/record.url?scp=84873026842&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD005967.pub4

DO - 10.1002/14651858.CD005967.pub4

M3 - Journal article

VL - n/a

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

SN - 1469-493X

IS - 6

M1 - CD005967

ER -